Company says enrollment is advancing in its ASCEND trial and a China combination study, with cash extended into second half of 2028 after a $143.7 million offering.
The clinical-stage oncology company set terms for its previously announced offering, expecting net proceeds of about $115.9 million to fund pipeline work into the second half of 2028.
